← Eichor
Study identifier: NCT06581432 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

Condition: Solid Tumours  ·  Sponsor: Boehringer Ingelheim

PhasePhase 2
Planned participants588
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a study for people with advanced cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with HER2 alterations can join the study. The purpose of this study is to find out whether a medicine called zongertinib helps people with advanced cancers with HER2 alterations. HER2 alterations can cause cancer. Zongertinib inhibits HER2. Participants are put into groups based on the type of advanced cancer they have, the type of HER2 alterations they have, and the dose of zongertinib they receive. Depending on the group they are in, participants take 1 of 2 different doses of zongertinib each day. Participants can continue the treatment as long as they benefit from it and can tolerate it. Participants visit the study site regularly. During many of the visits, the doctors check the size of the tumour and whether it has spread to other parts of the body. During all the visits, the doctors check participants' health and take note of any unwanted effects.

This description comes directly from the study's public registry record.

Talk to the study team

Boehringer Ingelheim  ·  1-800-243-0127  ·  clintriage.rdg@boehringer-ingelheim.com

Always discuss trial participation with your own doctor first.

Locations (90)

Alaska Oncology and Hematology, LLCAnchorage, Alaska, United StatesRecruiting
University of Arizona Comprehensive Cancer CenterTucson, Arizona, United StatesRecruiting
Precision NextGen OncologyBeverly Hills, California, United StatesRecruiting
Scripps Cancer Center Torrey PinesLa Jolla, California, United StatesRecruiting
Valkyrie Clinical TrialsLos Angeles, California, United StatesRecruiting
Yale University School of MedicineNew Haven, Connecticut, United StatesRecruiting
BRCR GlobalTamarac, Florida, United StatesRecruiting
Illinois Cancer SpecialistsArlington Heights, Illinois, United StatesRecruiting
Community MD Anderson Cancer Center - East Medical OncologyIndianapolis, Indiana, United StatesRecruiting
Maryland Oncology Hematology, ColumbiaColumbia, Maryland, United StatesRecruiting
Karmanos Cancer InstituteDetroit, Michigan, United StatesRecruiting
Presbyterian Healthcare ServicesAlbuquerque, New Mexico, United StatesRecruiting

+ 78 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06581432